Lead Plaintiff Deadline: February 25, 2019
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in during the relevant time frame, you have until February 25, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
In order to be included in the lawsuit, you must have incurred a loss on shares of purchased or acquired during the class period listed above.